While pancreatic cancer has an inherited or rapidly acquired chemoresistance, a meta-analysis of data from published clinical trials reported a significant improvement in overall survival (OS) among patients receiving chemotherapy . Nowadays, gemcitabine is widely accepted as the standard first-line therapy and as the reference treatment arm for clinical trials in this patient population [2, 3]. However, its anti-tumoral activity is disappointing because the response rate is around 10%, median survival about 6 months, and 1-year OS around 20%.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)